Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Haleon PLC ( (GB:HLN) ) has shared an update.
Haleon has repurchased 8,316,688 ordinary shares for cancellation as part of its ongoing share buyback programme launched in March 2026, executing trades between 11 and 15 May across venues including the London Stock Exchange and Cboe UK. Following these transactions, Haleon’s registered share capital stands at 8,871,945,578 ordinary shares, of which 12,130,560 are held in treasury, leaving 8,859,815,018 shares with voting rights, a key reference point for investors monitoring disclosure thresholds under UK transparency rules.
The buyback reduces the company’s free float and may enhance earnings per share over time, signalling management’s confidence in Haleon’s valuation and cash generation. The detailed trade data and regulatory disclosures, made available via the London Stock Exchange and the company’s website, underscore Haleon’s adherence to UK market abuse and transparency regulations, providing stakeholders with granular visibility into its capital management activities.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.15 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon plc is a global consumer health company listed in London and New York, focused on improving everyday health through branded over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin care, with flagship names including Advil, Panadol, Sensodyne, Centrum and Voltaren, used by over a billion consumers worldwide.
Average Trading Volume: 24,262,692
Technical Sentiment Signal: Sell
Current Market Cap: £29.52B
See more insights into HLN stock on TipRanks’ Stock Analysis page.